Inventor
MEYER CHRISTOPHE
FR34 patents
⚠️ This page may combine multiple inventors who share the name “MEYER CHRISTOPHE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
JANSSEN PHARMACEUTICA NV
13 patentsUS7943635B2May 17, 2011
Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
JANSSEN PHARMACEUTICA NV7 citations84
US7241777B2Jul 10, 2007
Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
JANSSEN PHARMACEUTICA NV14 citations84
US7834016B2Nov 16, 2010
Inhibitors of the interaction between MDM2 and p53
JANSSEN PHARMACEUTICA NV8 citations82
US10077261B2Sep 18, 2018
Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer
JANSSEN PHARMACEUTICA NV7 citations70
US8377961B2Feb 19, 2013
Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and P53
JANSSEN PHARMACEUTICA NV2 citations61
US11267804B2Mar 8, 2022
(R)-8-(1-((3-fluorophenyl)amino)ethyl)-N-(2-hydroxyethyl)-2-morpholinoquinoxaline-6-carboxamide for inhibiting phosphoinositide-3-kinase activity
JANSSEN PHARMACEUTICA NV0 citations59
US9598396B2Mar 21, 2017
Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors
JANSSEN PHARMACEUTICA NV0 citations51
US9150540B2Oct 6, 2015
Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors
JANSSEN PHARMACEUTICA NV1 citations51
US10526316B2Jan 7, 2020
Quinoxaline and pyridopyrazine derivatives as PI3Kβ inhibitors
JANSSEN PHARMACEUTICA NV0 citations49
US10894793B2Jan 19, 2021
Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors
JANSSEN PHARMACEUTICA NV0 citations48
US11130751B2Sep 28, 2021
Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors
JANSSEN PHARMACEUTICA NV0 citations47
US10202387B2Feb 12, 2019
Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors
JANSSEN PHARMACEUTICA NV0 citations39
US10087187B2Oct 2, 2018
Imidazopyridazine derivatives as PI3KB inhibitors
JANSSEN PHARMACEUTICA NV0 citations39
ADVA OPTICAL NETWORKING SE
4 patentsUS10122460B2Nov 6, 2018
Method and apparatus for automatic compensation of chromatic dispersion
ADVA OPTICAL NETWORKING SE2 citations71
US11233564B1Jan 25, 2022
Method and device for migrating data traffic from an existing optical WDM transmission system to a new optical WDM transmission system
ADVA OPTICAL NETWORKING SE0 citations49
US11582539B2Feb 14, 2023
Method and apparatus for management of a spectral capacity of a wavelength division multiplexing system
ADVA OPTICAL NETWORKING SE0 citations46
US10404397B2Sep 3, 2019
Wavelength division multiplexed telecommunication system with automatic compensation of chromatic dispersion
ADVA OPTICAL NETWORKING SE0 citations35
VIALARD JORGE EDUARDO
2 patentsTIBOTEC PHARM LTD
2 patentsLACRAMPE JEAN FERNAND ARMAND
2 patentsBONFANTI JEAN-FRANCOIS
2 patentsUS8883837B2Nov 11, 2014
Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication
BONFANTI JEAN-FRANCOIS0 citations44
US8278455B2Oct 2, 2012
5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
BONFANTI JEAN-FRANCOIS0 citations33